Inflammatory bowel diseases (IBDs) in humans are characterized in part by aberrant CD4-positive (CD41) T-cell responses. Currently, identification of foci of inflammation within the gut requires invasive procedures such as colonoscopy and biopsy. Molecular imaging with antibody fragment probes could be used to noninvasively monitor cell subsets causing intestinal inflammation. Here, GK1.5 cysdiabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET probe for CD41 T cells in the dextran sulfate sodium (DSS) mouse model of IBD. Methods: The DSS mouse model of IBD was validated by assessing changes in CD41 T cells in the spleen and mesenteric lymph nodes (MLNs) using flow cytometry. Furthermore, CD41 T cell infiltration in the colons of colitic mice was evaluated using immunohistochemistry. 89 Zr-labeled GK1.5 cDb was used to image distribution of CD41 T cells in the abdominal region and lymphoid organs of mice with DSS-induced colitis. Region-of-interest analysis was performed on specific regions of the gut to quantify probe uptake. Colons, ceca, and MLNs were removed and imaged ex vivo by PET. Imaging results were confirmed by ex vivo biodistribution analysis. Results: An increased number of CD41 T cells in the colons of colitic mice was confirmed by anti-CD4 immunohistochemistry. Increased uptake of 89 Zr-maleimide-deferoxamine (malDFO)-GK1.5 cDb in the distal colon of colitic mice was visible in vivo in PET scans, and regionof-interest analysis of the distal colon confirmed increased activity in DSS mice. MLNs from colitic mice were enlarged and visible in PET images. Ex vivo scans and biodistribution confirmed higher uptake in DSS-treated colons (DSS, 1.8 ± 0.40; control, 0.45 ± 0.12 percentage injected dose [%ID] per organ, respectively), ceca (DSS, 1.1 ± 0.38; control, 0.35 ± 0.09 %ID per organ), and MLNs (DSS, 1.1 ± 0.58; control, 0.37 ± 0.25 %ID per organ). Conclusion: 89 Zr-malDFO-GK1.5 cDb detected CD41 T cells in the colons, ceca, and MLNs of colitic mice and may prove useful for further investigations of CD41 T cells in preclinical models of IBD, with potential to guide development of antibody-based imaging in human IBD.
Thegut is a crucial compartment of the immune system. Lymphocytes reside in multiple locations throughout the gut, including the intestine, gut-associated lymphoid tissue such as Peyer patches and lymphoid follicles, and mesenteric lymph nodes (MLNs) (1) . The immune system must balance between tolerating the many food-and microbiome-derived antigens sampled from the gut and mounting an immune response to pathogens. Dysregulation of this delicate balance can lead to inflammatory bowel disease (IBD), a family of disorders characterized in part by abnormal and excessive T-cell responses (2) .
CD4-positive (CD41) T cells are known mediators of inflammation in IBD. Crohn's disease and ulcerative colitis each involves different subsets of CD41 T cells, including T helper type 1 (Th1), Th2, and Th17 (2) . Mouse models of IBD have helped advance understanding of how certain immune cell subsets, including CD41 T cells, contribute to gut inflammation. Several models, such as the CD41 CD45RB hi T-cell transfer model and the 2,4,6-trinitrobenzenesulfonic acid/oxalozone model, are CD41 T-cell-dependent and are used to study contributions of the adaptive immune system to IBD (3) . The dextran sulfate sodium (DSS) model of colitis is often used to investigate innate immune cell contributions, as it is characterized by an initial influx of neutrophils, followed by infiltration of T cells. Although CD41 T cells are not required for the induction of DSS colitis (4, 5) , they do increase in number in the colon as the disease progresses (6). Hall et al. (6) found that the peak number of CD41 T cells occurred on day 12 after initiation of DSS administration. In addition, changes in the percentage of T cells in spleen and MLNs can occur as early as day 1 (6) , indicating that during acute colitis the adaptive immune system is already changing, even though T cells are not required for induction. Given these findings, continued investigation into the role of CD41 T cells in the DSS colitis model is warranted.
Molecular imaging has been used to assess inflammation in murine models of colitis. 18 F-FDG and PET imaging were used in the DSS model to detect inflammation at several time points during progression of acute disease (7) and to correlate uptake in the colon with histologic damage and expression of perforin (8) . 18 F-FDG PET was used to identify inflammation in models with mild or severe chronic colitis, including the CD4 1 CD45RB high and Gai2 2/2 CD31 T-cell transfer models (9) . In humans with IBD, 18 F-FDG PET can identify inflammation with estimated sensitivity of 85% and specificity of 87% (10) and provide information complementary to standard methods such as colonoscopy and clinical symptom tracking (11) ; one caveat is that the highly variable physiologic uptake of 18 F-FDG PET in the gut may reduce its utility as a screening tool (12) .
Investigating specific cell subsets involved in IBD requires more specific probes. Molecular imaging with antibodies enables imaging of cell-surface biomarkers (13) , and antibodies have been used to image immune cells in models of colitis. Kanwar et al. used a nondepleting intact anti-CD4 antibody for SPECT imaging of CD41 T cells in DSS colitis and showed that uptake in the lower abdomen correlated with disease severity and the number of CD41 T cells present (14) . The integrin b 7 subunit, expressed on lymphocytes activated in Peyer patches and MLNs, was recently used as a target for SPECT imaging in DSS-treated colitic mice (15) . Dearling et al. developed fragments of the antiintegrin b 7 antibody probe and used them to image lymphocytes in the intestines of colitic mice (16) .
We previously described GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment, and demonstrated its use in tracking immune system reconstitution posthematopoietic stem cell transplant (17) . Subsequent studies investigated the effect of protein dose on image contrast and biologic effect on CD41 T cells and showed that low-dose GK1.5 cDb produces high-contrast images of lymphoid organs with minimal effects on CD41 T-cell function in vivo (18) . Here, the utility of anti-CD4 GK1.5 cDb as an immuno-PET probe for regions of CD41 T-cell infiltration in the murine DSS model of IBD has been evaluated and correlated with ex vivo biodistribution analysis, flow cytometry, and immunohistochemistry of CD41 T cells in the intestines and lymphoid organs.
MATERIALS AND METHODS

Animals
Female C57BL/6 mice 6-12 wk old were obtained from Jackson Laboratories and housed by the Department of Laboratory Animal Medicine at the University of California, Los Angeles, under specific pathogen-free conditions. Animal studies were conducted under protocols approved by the institutional Chancellor's Animal Research Committee.
Induction and Assessment of Colitis DSS (40,000 kDa; Sigma) was dissolved in autoclaved tap water, sterile-filtered, and provided ad libitum. On the basis of published literature (6) and dose-finding pilot studies (data not shown), we determined that 4% DSS administered for 5 d induced infiltration of mononuclear cells into the colon by day 12. Regular water was restored on day 6. Mice were weighed every day and examined for signs of colitis, which was evaluated by a disease activity index modified from Sha et al. (19) : weight loss (0, none; 1, 1%-4%; 2, 5%-10%; 3, 11%-20%; 4, .20%), fecal blood (0, none; 2, blood present in stool; 4, gross bleeding from anus), and stool consistency (0, normal; 2, loose stools; 4, diarrhea). On day 12, the mice were euthanized, and the colon, cecum, and MLNs were removed. MLNs were pooled per individual mouse, weighed, and divided by the number of MLNs collected to get the average weight of 1 MLN for each mouse.
GK1.5 cDb Administration and PET/CT Imaging
Antimouse CD4 GK1.5 cDb was produced, purified, and radiolabeled as described previously (17, 18) . 89 Zr-maleimide-deferoxamine (malDFO)-GK1.5 cDb (2 mg; 0.38 MBq) was injected intravenously. One hour before imaging, 100 mL of Gastrografin (diatrizoate meglumine and diatrizoate sodium solution; Bracco) were administered orally for CT contrast of the upper gastrointestinal tract. Immediately before imaging, the mice were anesthetized with 2% isoflurane, and 100 mL of Gastrografin were administered intrarectally for large-intestine contrast. PET and CT scans were acquired 20 h after injection as previously described (18) . CT scans were acquired on the CrumpCAT, a fast micro-CT prototype developed at our institution (20) . Ex vivo PET/CT scans of harvested colons, ceca, and MLNs were acquired using the same parameters as above. PET/CT images were viewed using AMIDE (http://amide.sourceforge.net). Biodistribution analysis was conducted as previously described (18) . Additionally, colons and ceca were fixed and processed for histopathologic and immunohistochemical analysis.
For quantitative analysis of intestinal uptake, first the skeleton was manually removed from the CT image using several regions of interest (ROIs). A 3-dimensional isocontour ROI around the contrast-enhanced small and large intestines (gut ROI) was created. After gut ROI quantification, a cylindric ROI was drawn around a representative colon, from the anus to just below the kidneys, and used on every mouse to reproducibly crop out the same amount of anatomy. A 3-dimensional isocontour ROI was then drawn on the remaining distal colon and quantified.
Flow Cytometry
Lymphocytes in MLNs and spleens were analyzed by flow cytometry. Organ harvesting and preparation were performed as described previously (18) .
Statistical Analysis
Prism software (GraphPad) was used to perform 2-tailed Student t tests. A P value of less than 0.05 was considered to be statistically significant. For t tests on organs from the ex vivo biodistribution study, the HolmSidak correction for multiple comparisons was applied. Values are reported as mean 6 SD unless indicated otherwise.
RESULTS
DSS-Induced Colitis Results in Gross Anatomic Changes
Mice treated with 4% DSS for 5 d (Fig.  1A) showed weight loss beginning on day 6. On day 12, the weight of DSS-treated mice was significantly reduced to 87% 6 0.06% of initial weight, whereas control mice did not display any weight loss (P , 0.0001; n 5 8) (Fig. 1B) . DSS-treated mice also had significantly higher scores on the disease activity index than control mice as a result of increased weight loss, loose stool, and fecal bleeding (Supplemental Fig. 1A ; supplemental materials are available at http:// jnm.snmjournals.org).
Colons from DSS-treated mice were significantly shorter (P , 0.05) (Fig. 1C) and heavier (data not shown) than control colons. The colon weight-to-length ratio was significantly higher in colitic mice (P , 0.001) (Fig. 1D) . Individual MLNs from DSS-treated mice weighed more on average (6.1 6 3.0 mg; range, 1.4-11 mg) than MLNs from control mice (2.1 6 1.1 mg; range, 0.4-4.4 mg; P , 0.0001; n 5 8 mice) (Fig. 1E) ; furthermore, average MLN cellularity was higher in DSS mice (n 5 4 mice; Supplemental Fig. 2) .
Histopathologic analysis showed that colons from DSS-treated mice had epithelial cell loss, crypt destruction, and infiltration of inflammatory cells into the mucosa (Supplemental Figs. 1B and  1C ). These signs were severe but localized in most mice. DSStreated mice also had significantly more lymphoid aggregates throughout the colon (Supplemental Fig. 1D ).
Changes in CD41 T Cells in DSS-Treated Mice
Anti-CD4 immunohistochemical staining showed increased infiltration of CD41 T cells into the colons of DSS-treated mice ( Fig. 2A) . CD41 cells were on average 0.66% 6 0.46% of the total cells in each section of colon in control mice, whereas DSStreated mice had an average of 1.9% 6 1.5% CD41 cells (P , 0.05; control n 5 12, DSS n 5 13) (Fig. 2B) . Ceca from colitic mice did not show a significant increase in the percentage of CD41 T cells (Supplemental Fig. 3A) . Changes in CD41 T cells in spleens and MLNs were evaluated by flow cytometry. The percentage of CD451 CD41 cells in the spleen increased slightly in DSS mice, though not significantly (control, 20.6% 6 4.4%; DSS, 23.7% 6 4.1%; n 5 11 mice) (Supplemental Fig.  3B ). The percentage of CD451 CD41 cells in MLNs of DSS mice decreased significantly (control, 33.0% 6 9.4%; DSS, 24.6% 6 6.1%; P , 0.05; control n 5 9 mice; DSS n 5 10 mice) (Fig. 2C) . 
Organs of interest are axillary LN (ALN), bone (B), cervical LN (CLN), inguinal LN (ILN), kidney (K), liver (Li), popliteal LN (PLN), mesenteric LN (MLN), and spleen (Sp). Distal colon ROI is indicated by red dotted line. (B) Representative CT and PET/CT images of ROI drawn around distal colon from control (top) and DSS-treated (bottom) mice. (C)
Quantitative analysis of ROIs drawn around distal colon or small and large intestines, using 3-dimensional isocontour ROI function of AMIDE (control, n 5 6; DSS, n 5 7). *P , 0.005.
Immuno-PET Imaging of CD4 in Colitic Mice
GK1.5 cDb was site-specifically conjugated to malDFO and radiolabeled with 89 Zr. Radiolabeling efficiency was more than 99% (n 5 3). Specific activity was 0.19 6 0.023 MBq/mg (9.9 · 10 5 6 1.2 · 10 5 MBq/mmol), and radiochemical purity was more than 99% (n 5 3). 89 Zr-malDFO-GK1.5 cDb (2 mg; 0.38 MBq) was injected into groups of mice (2 experiments of 4 mice per group). PET imaging showed tracer uptake in spleens and lymph nodes, consistent with previous results of studies of untreated mice (Fig. 3A) (18) . PET scans of colitic mice demonstrated increased signal from MLNs. The colons of colitic mice also showed uptake of 89 Zr-malDFO-GK1.5 cDb, whereas the control mice showed little to no uptake in the colon (Fig. 3A) . Oral and intrarectal instillation of CT contrast agent delineated the intestine clearly on the CT scan (Supplemental Figs. 4A and 4B ) and enabled 3-dimensional isocontour ROIs of the complete small and large intestines (gut ROI) and of the distal colon only (colon ROI) to be created on the basis of intensity of CT signal after manual removal of the skeleton (Supplemental Fig. 4C; Fig. 3B ). DSS mice had significantly increased uptake in the colon ROI (P , 0.005) but not the gut ROI compared with control mice (P 5 0.548) (Fig. 3C) ; spillover signal from the kidneys into the ROI may have masked actual differences.
Ex vivo scans confirmed the results of the in vivo scans, showing visibly increased uptake in colons, ceca, and MLNs from DSS mice (Fig. 4) . Biodistribution studies showed that total activity was higher in DSS-treated colons, ceca, and MLNs (3.1-fold, 3.9-fold, and 3.0-fold, respectively) ( Fig. 5A; Table 1 ). Comparing concentration of activity (percentage injected dose per organ [%ID/g]) in organs known to be affected by DSS-induced colitis (colon, cecum, and MLN) did not result in significant changes in uptake ( Fig. 5B ; Supplemental Table 1 ).
DISCUSSION
Aberrant activation and infiltration of CD41 T cells is a hallmark of IBD in humans and in numerous mouse models of IBD. The contribution of CD41 T cells to DSS colitis is still controversial. Although the DSS model does not require T cells for induction of colitis (4, 5) , they still infiltrate into the colon (6), and CD41 T cells appear to play a role in the chronic stage of colitis (21, 22) . Adoptive transfer of DSS-primed CD41 T cells into recipient mice treated with DSS resulted in exaggerated colitis (23) . Conversely, athymic CD-1 nu/nu mice treated with DSS developed more severe clinical signs of colitis than normal mice, suggesting that T cells may be protective in DSS colitis (5) . Molecular imaging could be of use to further investigate how CD41 T cells affect the induction and progression of DSS colitis.
The DSS model and resulting changes in CD41 T cells were validated using quantitative immunohistochemistry and flow cytometry. Radiolabeled anti-CD4 GK1.5 cDb was used to see if the presence of increased CD41 T cells could be visualized and quantified with immuno-PET. 89 Zr-malDFO-GK1.5 cDb successfully detected CD41 T cells in the colons and MLNs of colitic mice, and quantification of the distal colon region with ROI analysis showed that uptake significantly increased in colitic mice. This result is consistent with other studies, which report that the most severe damage in the DSS model occurs in that region (4, 24) . Quantifying uptake in the gut ROI, which included both the small and the large intestines, was challenging because the probe cleared through the kidneys, resulting in signal spillover into the anterior region of the ROI; differences in the gut ROIs were not significant between control and DSS-treated mice.
Significantly increased uptake of 89 Zr-malDFO-GK1.5 cDb in the distal colon ROI, as well as in MLNs, was supported by the ex vivo organ scans. Interestingly, uptake was also increased in the ceca of colitic mice, although we did not observe increased CD41 T cells by immunohistochemistry in colitic ceca; this may be due at least in part to enhanced permeability of the cecum due to DSSinduced inflammation. Quantification of uptake via ex vivo biodistribution analysis confirmed a significant increase in %ID per organ for colons, MLNs, and ceca of DSS-treated mice; however, the concentration of activity in these organs (presented as %ID/g) was not significantly higher in DSS mice. In colons of DSS mice, this may be explained by the finding that they were heavier than control colons. In DSS-treated MLNs, although the percentage of CD41 T cells decreased, MLNs were significantly enlarged, which suggests that both CD41 T cells and other types of immune cells were present in higher total numbers, resulting in increased size but not increased concentration.
In in situ and ex vivo immuno-PET images, colitic MLNs appear to have a higher %ID/g than control MLNs, but ex vivo biodistribution analysis indicates that they have the same %ID/g. This finding is explained by the partial-volume effect, in which the concentration of activity in organs near the resolution of the PET scanner is underestimated (17) . Colitic MLNs were dramatically enlarged and more easily detected by immuno-PET than the tiny control MLNs. The partial-volume effect, especially in the context of murine lymph nodes, has been observed and discussed in previous work from our laboratory (17) . The observation of signal from enlarged MLNs in colitic mice demonstrates the importance of MLNs and associated lymphatics in the development of DSS colitis and raises the possibility of the prognostic value of inflammatory staging sites such as MLNs, though more work is needed to fully understand the timing and cellular dynamics of MLN enlargement.
These results confirm and expand on the work of Kanwar et al., who used 111 In-labeled intact anti-CD4 antibody for SPECT imaging of CD41 T cells in DSS mice; in that work, a protein dose of 350 mg was used (14) . We previously explored protein doses and found that amounts as low as 2 mg of GK1.5 cDb enabled imaging of CD41 T cells in the lymph nodes and spleen with minimal biologic effects (18) . Here, 2 mg of GK1.5 cDb were sufficient to image CD41 T cells in the DSS model. Furthermore, Kanwar et al. drew an ROI that encompassed the entire lower abdomen and referred to this as ''colon uptake'' but did not discuss signal from CD41 T cells in the MLN (14) , which were likely included in the ROI. Therefore, while whole-abdomen ROIs may have prognostic value in IBD, they must be interpreted with consideration of the presence of MLNs and associated lymphatic tissue.
Although GK1.5 cDb enables visualization of total CD41 cells in the gut, it does not provide information about CD41 T-cell subsets such as Th1, Th2, Th17, or regulatory T cells, which is disadvantageous given the different pro-and antiinflammatory roles of each of these subsets. However, GK1.5 cDb can be used to identify sites of CD41 T-cell accumulation, followed by detailed analysis with traditional methods such as biopsy to determine the subsets present as needed. Further studies using GK1.5 cDb in mouse models of IBD could include imaging of CD4 in a T-celldependent model or imaging at several time points during the development of colitis to investigate the course of T-cell infiltration into the intestines and MLNs.
CD41 T cells play a key role in human IBD, and identifying them throughout the bowel could be useful to monitor disease severity and predict treatment success. Imaging is less intrusive than colonoscopies, which are uncomfortable for patients and carry a risk of bowel perforation; furthermore, inflammation can vary depending on the position within the bowel. Anti-CD4 immuno-PET could provide an overview of inflammatory sites throughout the intestines. Other immune targets, including granulocytes (24), E-selectin (25) , and CXCL8 (12) , have been imaged in IBD patients. Aarntzen et al. suggest that anti-CXCL8 imaging could be a tool for making decisions about immune-modulating treatment (12); a similar application could apply for anti-CD4 imaging. 
